ODYSSEY OUTCOMES trial: Alirocumab reduces nonfatal cardiovascular and fatal events


The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared Alirocumab ( Praluent ) with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome ( ACS ) in 18,924 patients.
Alirocumab has reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.

A pre-specified analysis has determined the extent to which Alirocumab has reduced total ( first and subsequent ) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES.

With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with Alirocumab compared with placebo.

Alirocumab has reduced total nonfatal cardiovascular events ( hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93 ) and death ( HR=0.83; 95% confidence interval: 0.71 to 0.97 ) in the presence of a strong association between nonfatal and fatal event risk.

In patients with acute coronary syndrome, the total number of nonfatal cardiovascular events and deaths prevented with Alirocumab was twice the number of first events prevented.
Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after acute coronary syndrome. ( Xagena )

Szarek M et al, J Am Coll Cardiol 2019;73:387-396

XagenaMedicine_2019



Indietro

Altri articoli

The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...


Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...


In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein...


ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...


Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...


A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...


Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...